Breaking News
Investing Pro 0

5 Best and Worst Performing Small-Cap Stocks in October 2022

By ValueWalkStock MarketsNov 08, 2022 01:45AM ET
www.investing.com/analysis/5-best-and-worst-performing-smallcap-stocks-in-october-2022-200632070
5 Best and Worst Performing Small-Cap Stocks in October 2022
By ValueWalk   |  Nov 08, 2022 01:45AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
BHVN
-0.60%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ACMR
+0.25%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NGM
-0.37%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
IMVT
+3.72%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AKUS
+0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CANO
+6.04%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Small-cap stocks can offer big returns quickly, especially when the economy is rebounding from a slowdown. This is because businesses witness robust earnings growth when the economy is recovering.

On the other hand, small-cap stocks can also offer significant losses because of their volatile nature. To give an idea of the gains you can make and losses you can incur, discussed below are the five best and worst-performing small-cap stocks in October 2022.

Five Best-Performing Small-Cap Stocks In October 2022

We have used the October return data from finviz.com to develop the five best and worst-performing small-cap stocks in October 2022. Here are the five best-performing small-cap stocks in October 2022:

  1. Akouos (95%)

Founded in 2016 and headquartered in Boston, Mass., this company develops precision genetic medicines to restore and preserve hearing in genetically-defined patients. Akouos (NASDAQ:AKUS) shares are up by almost 52% year to date and up over 312% in the last three months.

As of this writing, Akouos shares are trading above $13 with a 52-week range of $2.32 to $13.35, giving the company a market capitalization of more than $485 million.

  1. Immunovant (101%)

Founded in 2018 and headquartered in New York City, it is a clinical-stage biopharmaceutical company focusing on providing normal lives to patients with autoimmune diseases. Immunovant (NASDAQ:IMVT) shares are up by almost 40% year to date and up almost 151% in the last three months.

As of this writing, Immunovant shares are trading above $11 with a 52-week range of $3.15 to $12.42, giving the company a market cap of more than $1.40 billion.

  1. FingerMotion (118%)

Founded in 2014 and headquartered in New York City, this company offers mobile payment and recharge services in China. FingerMotion Inc (NASDAQ:FNGR) shares are down by almost 4% year to date but are up by almost 512% in the last three months.

FingerMotion shares are trading above $6.80 with a 52-week range of $0.62 to $9.80, giving the company a market capitalization of more than $320 million.

  1. Tango Therapeutics (122%)

Founded in 2017 and headquartered in Boston, Mass., this company discovers novel drugs to deliver targeted therapies to cancer patients. Tango Therapeutics (NASDAQ:TNGX) shares are down by almost 32% year to date but are up by almost 75% in the last three months.

As of this writing, Tango Therapeutics shares are trading at above $7.40, with a 52-week range of $3.18 to $14.31, giving the company a market capitalization of more than $650 million.

  1. Biohaven (163%)

Founded in 2013 and headquartered in New Haven, Conn., Biohaven Pharmaceutical Holding (NYSE:BHVN) is a modern pharmaceutical company aiming to change people's lives with unmet medical needs.

Biohaven shares are trading above $14 with a 52-week range of $5.54 to $17.39, giving the company a market capitalization of more than $940 million.

Five Worst Performing Small-Cap Stocks in October 2022

These were the five worst-performing small-cap stocks in October 2022:

  1. Nutex Health (-46%)

It is a technology-enabled healthcare services company founded in 2011 and headquartered in Houston, Texas. Nutex Health (NASDAQ:NUTX) shares are down by almost 83% year to date and down over 79% in the last three months.

As of this writing, Nutex Health shares are trading above $0.72 with a 52-week range of $0.50 to $52.80, giving the company a market capitalization of more than $480 million.

  1. ACM Research (-49%)

Founded in 1998 and headquartered in Fremont, Calif., this company develops, makes, and sells single-wafer wet cleaning equipment. Acm Research (NASDAQ:ACMR) shares are down by almost 77% year to date and down almost 66% in the last three months.

As of this writing, ACM Research shares are trading above $6.50 with a 52-week range of $5.46 to $37.12, giving the company a market capitalization of more than $360 million.

  1. TuSimple Holdings (-55%)

Founded in 2015 and headquartered in San Diego, Calif., this company operates and develops autonomous trucks. Tusimple Holdings (NASDAQ:TSP) shares are down by over 90% year to date and down over 71% in the last three months.

As of this writing, TuSimple Holdings shares are trading above $2.70 with a 52-week range of $2.83 to $43.79, giving the company a market cap of more than $760 million.

  1. Cano Health (-59%)

Founded in 2009 and headquartered in Miami, Fla., this company operates primary care centers and supports related medical practices in primary care for seniors. Cano Health (NYSE:CANO) shares are down by over 62% year to date and down over 45% in the last three months.

As of this writing, Cano Health shares are trading above $3.30 with a 52-week range of $3.30 to $12.87, giving the company a market capitalization of more than $1.60 billion.

  1. NGM Biopharmaceuticals (-59%)

Founded in 2007 and headquartered in South San Francisco, Calif., this company discovers and develops therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. NGM Biopharmaceuticals (NASDAQ:NGM) shares are down by almost 72% year to date and down over 69% in the last three months.

As of this writing, NGM Biopharmaceuticals shares are trading above $4.60 with a 52-week range of $2.92 to $21.63, giving the company a market cap of more than $400 million.

5 Best and Worst Performing Small-Cap Stocks in October 2022
 

Related Articles

5 Best and Worst Performing Small-Cap Stocks in October 2022

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email